Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Council OKs Applications Based on Data from Public Domain for 3 Drugs Including Lidocaine
July 14, 2015
- Govt, Pharma Leaders to Meet in August for Drafting of “Comprehensive Strategy”
July 13, 2015
- Q&A Document on GMP for APIs Reaches Step 4: ICH Meeting in Fukuoka
July 13, 2015
- MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
- FY2015 Survey on Generic Use to Get Underway, Results Out in Autumn
July 9, 2015
- JPMA to Cooperate in AMED’s DISC Project: President
July 9, 2015
- Govt to Stockpile Enough Cell Culture-Based H5N1 Pre-Pandemic Vaccines from Kaketsuken for 2.5 Million People
July 9, 2015
- Heart Failure Added to Clinically Significant ADR List for Xalkori
July 8, 2015
- MHLW Calls for Revision of Package Insert for Influenza HA Vaccine, Others
July 8, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
- Govt to Stockpile Pre-Pandemic Flu Vaccine Based on Indonesia Strain in FY2015
July 7, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 22 - July 5
July 6, 2015
- MHLW Approves Gilead’s Harvoni, Other Products
July 6, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- Official Denies Report, Says Govt Won’t Ask Research-Driven Firms to Make Generics
July 3, 2015
- MHLW to Accept Applications for Sakigake Designation for Regenerative Medicine Products, Medical Devices from Sept. 14
July 3, 2015
- LDP, Komeito Lawmakers’ Group Formed to Fight Hepatitis
July 2, 2015
- Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…